Part 1 in our new “Rising Stars” series featuring – Dr. Tyler Parsons Written by Heidi Cascarano and David Wallace Early Blood Clot Mysteries Like many MPN patients, Tyler’s journey to diagnosis was a long and winding road, marked by mysterious symptoms that remained unexplained for years. For Tyler, these symptoms took the form of […]
Promising New Gene Target to Combat Blood Cancer
A group of biomedical researchers from around the world, including Dr. Alexander Bick at Vanderbilt University Medical Center, have developed a new technique called PACER to measure the growth rate of abnormal blood stem cells. This breakthrough could help doctors reduce their patients future risk of blood cancer. Why This Matters: The Importance of Understanding […]
9 Tips for Reducing Risks of Thrombosis in MPNs
by David Wallace Understanding Thrombosis in MPN Patients Myeloproliferative neoplasms (MPNs) are a group of chronic blood cancers that affect the normal functioning of blood cells. People living with MPNs, such as polycythemia vera (PV), essential thrombocythemia (ET), and myelofibrosis (MF), have an increased risk of developing blood clots, or thrombosis. Thrombosis can lead to […]
Dr. Srdan Verstovsek Joins Kartos Therapeutics as CMO
World-Renowned Physician-Scientist and Global Expert in Myeloproliferative Neoplasms Will Be Instrumental in Advancing the Development of Navtemadlin and Other Innovative Therapies to Improve the Lives of Cancer Patients REDWOOD CITY, Calif., March 02, 2023–(BUSINESS WIRE)–Kartos Therapeutics, Inc. (“Kartos” or the “Company”), a clinical stage biopharmaceutical company dedicated to the development of novel, targeted therapeutics that […]
Modified CALR Mutation helps Identify New Drug Targets for MPN Cancer
Summary The research article discusses myeloproliferative neoplasms (MPN), a type of cancer that affects the blood and bone marrow. It focuses on the Calreticulin (CALR) mutation found in 20% to 25% of MPN patients (with ET and MF) and, which is a potential target for new drug therapies. The authors describe a novel approach using […]
- « Previous Page
- 1
- 2
- 3
- 4
- 5
- …
- 40
- Next Page »
